Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 566 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vaginal Diseases Clear all

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Sterility, Female
Interventions: Traditional laparoscopy, Single site laparoscopy, V-Notes surgery; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Vaginal Health, Bacterial Vaginosis
Interventions: Boric Acid Suppository; Dietary Supplement
Lead sponsor: Love Wellness; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Pelvic Organ Prolapse
Interventions: Exair Prolapse Repair System, Total Native Tissue Repair; Device · Procedure
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 13
States / cities: Savannah, Georgia • Fort Wayne, Indiana • Dearborn, Michigan + 9 more

Conditions: Atrophic Vaginitis, Atrophy, Vaginitis
Interventions: PVC (daily for 21 days, 7 days off), PVC (twice weekly); Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 480 participants
Timeline: 2005 – 2007
U.S. locations: 32
States / cities: Tucson, Arizona • Encinitas, California • San Diego, California + 28 more

Conditions: Stress Urinary Incontinence, Intrinsic Sphincter Deficiency
Interventions: Prefyx PPS™ System, Advantage ™ System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB), Fluconazole; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Conditions: Vaginitis
Interventions: BDMax Vaginal Panel; Diagnostic Test
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Appendicitis, Cholelithiasis, Gallstones
Interventions: Transvaginal Appendectomy, Transvaginal Cholecystectomy; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stress Urinary Incontinence, Urethral Hypermobility, Cystocele
Interventions: Voiding trial; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Solid Tumors With PTCH1 Loss-of-function Mutations
Interventions: ENV-101 (taladegib); Drug
Lead sponsor: Endeavor Biomedicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Santa Rosa, California • Tampa, Florida + 13 more

Conditions: Estrogen Receptor Positive Breast Cancer, Breast Cancer
Interventions: ESTRING, Replens, Vagifem; Drug
Lead sponsor: Polly A. Niravath, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dyspareunia
Interventions: Vaginal Moisturizer, Vaginal Dilator; Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: New York, New York • Providence, Rhode Island

Conditions: Refractory Overactive Bladder
Interventions: Not listed
Lead sponsor: University of Oklahoma; Other
Eligibility: 21 Years to 99 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Amniotic Fluid Leakage
Interventions: AL-SENSE Diagnostic Absorbent Panty liner; Device
Lead sponsor: Western Galilee Hospital-Nahariya; Government
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Malignant Neoplasm, Recurrent Penile Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Refractory Malignant Neoplasm, Stage IV Anal Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8
Interventions: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Tract Infections
Interventions: D-Mannose; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years and older · Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Vulvar and Vaginal Atrophy
Interventions: Estrace® Cream, Estradiol Vaginal Cream, Vehicle Cream; Drug
Lead sponsor: Prasco LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 27
States / cities: Sacramento, California • San Diego, California • Denver, Colorado + 23 more

Conditions: Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma
Interventions: Biospecimen Collection, Prasterone, Survey Administration; Procedure · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Vaginal Infection
Interventions: TOL-463 Vaginal ovule, TOL-463 Vaginal gel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8
Interventions: Biospecimen Collection, Placebo Administration, Probiotic, Questionnaire Administration; Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Bacterial Vaginoses
Interventions: Metronidazole, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Candida Vulvovaginitis
Interventions: Ibrexafungerp, Placebo; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more

Search by objective public record fields.

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Patient-centered Outcomes After Permanent Female Sterilization Procedure(POPS Trial)

A Single Group Study to Evaluate the Effects of a Boric Acid Suppository on Vaginal Health.

Exair® Versus Native Tissue Repair for Prolapse

Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis

Post Market Clinical Study to Evaluate a Mid-Urethral Vaginal Tape Procedure With a Pre-Pubic Delivery Approach, for the Treatment of Stress Urinary Incontinence

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Diagnostic Accuracy By Providers Study

Minimally Invasive Surgery: Using Natural Orfices

Comparing Voiding Trials After Midurethral Sling for Stress Incontinence

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia

Vaginal Electrical Stimulation Versus Neuromodulation

Pivotal Study of the Al-Sense Study Protocol

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Nutraceutical Efficacy for rUTI

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

A Randomized Controlled Trial of Treatment of Bacterial Vaginosis

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)